We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Join our family
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Register for Drug Discovery & Development Symposium 2025
The PVRI Drug Discovery and Development Symposium 2025 #DDDS2025 will be taking place on 16-17 June 2025 in Amsterdam. See our event page for more details and register your place!
We are thrilled to announce that our Drug Discovery and Development Symposium 2025 (#DDDS2025) will take place on 16-17 June 2025 in the Mercure Hotel Amsterdam City, Amsterdam, Holland.
Perspectives on Global Epidemiology Challenges is part of the Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
Presentations: Is there evidence for different phenotypes of PH in ILD? Treatment of pulmonary vascular disease in ILD: as early as possible or only in severe PH?
Although right ventricle (RV) dysfunction drives clinical worsening in pulmonary hypertension (PH), information about RV function has not been well integrated in PH risk assessment. The gold standard for assessing RV function and ventriculo-arterial coupling is the construction of multi-beat pressure–volume (PV) loops.
In the study “Echocardiographic grading of right ventricular afterload in left heart disease: relation to right ventricular function, pulsatile and resistant load, and outcome,” Bech-Hanssen et al. addressed an interesting topic about severity gradation using right ventricular (RV) afterload echocardiographic assessment.
The history of advances in understanding pulmonary circulation is long, dating to the 13th century. Subsequent centuries produced halting progress until the 20th century when investigators applied right heart catheterization and light-microscopy to better understand the physiology and pathology of pulmonary hypertension (PH). The work of Paul Wood, Cornelis Wagenvoort, and others during the first seven decades of the 20th century set the stage for five decades of extraordinary progress.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
We are delighted to invite our members to submit suggestions for the next PVRI Digital series, which is scheduled to start in September 2025 and will run for 18 months.
Rubin Tuder, a trailblazer in the field of pulmonary vascular biology and a driving force in PH research, has been honoured with the PVRI Lifetime Achievement Award for 2025. This prestigious Award is given annually at the PVRI Annual Congress to a senior PH investigator or clinician for their exceptional and outstanding contributions to the field of pulmonary vascular disease and to PVRI. This recognition celebrates his unparalleled contributions to science, mentorship, and the global PH community.
The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School—invites applications for an advanced fellowship in pulmonary heart disease starting July 1, 2026. This training program is sponsored by the Center for Pulmonary Heart Disease at the Brigham and Women’s Hospital. The position offers an intensive clinical experience including evaluation and management of both inpatients and outpatients with pulmonary vascular disease and right heart dysfunction or failure. In addition, applicants are strongly encouraged to participate in a translational or clinical research program.
